Literature DB >> 26051689

Telmisartan.

Ahmed H H Bakheit1, Ahmed A Abd-Elgalil2, Bakheit Mustafa3, Anzarul Haque4, Tanveer A Wani5.   

Abstract

Telmisartan is an angiotensin-II receptor antagonist (ARB) used in the treatment of hypertension. Generally, angiotensin-II receptor blockers such as telmisartan bind to the angiotensin-II type 1 receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. The present study gives a comprehensive profile of telmisartan, including detailed nomenclature, formulae, elemental analysis, and appearance of the drug are mentioned. The uses and applications and the several methods described for its preparation of the drug are outlined. The profile contains the physicochemical properties including: pKa value, solubility, X-ray powder diffraction, melting point, and methods of analysis (including compendial, electrochemical, spectroscopic, and chromatographic methods of analysis). Developed validated stability-indicating (HPLC and biodiffusion assay methods under accelerated acidic, alkaline, and oxidative conditions, in addition to effect of different types of light, temperature, and pH. Detailed Pharmacology also presented (Pharmacological actions, Therapeutic uses and Dosing, Interactions, and adverse effects and precautions). More than 80 references were given as a proof of the above-mentioned studies.
© 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Description; Method of analysis; Pharmacokinetics; Physical characteristics; Spectral properties; Stability; Synthesis; Telmisartan; Uses

Mesh:

Substances:

Year:  2015        PMID: 26051689     DOI: 10.1016/bs.podrm.2015.01.003

Source DB:  PubMed          Journal:  Profiles Drug Subst Excip Relat Methodol        ISSN: 1871-5125


  7 in total

1.  Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis.

Authors:  Lu Huang; Liu Yang; Jie Huang; Hong-Yi Tan; Shi-Kun Liu; Cheng-Xian Guo; Xiao-Cong Zuo; Guo-Ping Yang; Qi Pei
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

2.  Transdermal Delivery of Telmisartan: Formulation, in vitro, ex vivo, Iontophoretic Permeation Enhancement and Comparative Pharmacokinetic Study in Rats.

Authors:  Mahmoud Teaima; Rehab Abdelmonem; Yomna A Adel; Mohamed A El-Nabarawi; Tayseer M El-Nawawy
Journal:  Drug Des Devel Ther       Date:  2021-11-10       Impact factor: 4.162

Review 3.  Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Authors:  Michael E Salacz; Richard E Kast; Najmaldin Saki; Ansgar Brüning; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

4.  Novel biphenyl ester derivatives as tyrosinase inhibitors: Synthesis, crystallographic, spectral analysis and molecular docking studies.

Authors:  Huey Chong Kwong; C S Chidan Kumar; Siau Hui Mah; Tze Shyang Chia; Ching Kheng Quah; Zi Han Loh; Siddegowda Chandraju; Gin Keat Lim
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

5.  UTILISATION ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN BOSNIA AND HERZEGOVINA FOR THE TIME-PERIOD 2013-2015.

Authors:  Kenan Selmanovic; Svjetlana Loga Zec; Nenad Vanis; Lamija Zecevic; Manja Setkic; Azra Rasic; Enver Zerem
Journal:  Mater Sociomed       Date:  2016-03-25

6.  Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity.

Authors:  Wanyu Wang; Ailing Song; Yiming Zeng; Xiaoyang Chen; Yixiang Zhang; Yonghong Shi; Yihua Lin; Wen Luo
Journal:  BMC Cardiovasc Disord       Date:  2018-07-03       Impact factor: 2.298

7.  Selective Arylation of 2-Bromo-4-chlorophenyl-2-bromobutanoate via a Pd-Catalyzed Suzuki Cross-Coupling Reaction and Its Electronic and Non-Linear Optical (NLO) Properties via DFT Studies.

Authors:  Usman Nazeer; Nasir Rasool; Aqsa Mujahid; Asim Mansha; Muhammad Zubair; Naveen Kosar; Tariq Mahmood; Ali Raza Shah; Syed Adnan Ali Shah; Zainul Amiruddin Zakaria; Muhammad Nadeem Akhtar
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.